Low‐dose fludarabine and cyclophosphamide combined with rituximab in the first‐line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long‐term results of project Q‐lite by the Czech CLL Study Group-Reference-Cited by-同舟云学术

Low‐dose fludarabine and cyclophosphamide combined with rituximab in the first‐line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long‐term results of project Q‐lite by the Czech CLL Study Group

Published:2021-02-22 Issue:4 Volume:193 Page:769-778
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Smolej Lukáš¹^ORCID,Brychtová Yvona²,Cmunt Eduard³,Doubek Michael²,Špaček Martin³,Belada David¹,Šimkovič Martin¹,Stejskal Lukáš⁴,Zygulová Irena⁴,Urbanová Renata⁵,Brejcha Martin⁶,Zuchnická Jana⁷,Móciková Heidi⁸,Kozák Tomáš⁸,

Affiliation:

1. 4th Department of Internal Medicine – Haematology Faculty of Medicine University Hospital Hradec KrálovéCzech Republic

2. Department of Internal Medicine – Haematology and Oncology University Hospital BrnoCzech Republic

3. First Department of Medicine – Haematology General University Hospital PragueCzech Republic

4. Haematology/Tranfusiology Department Silesian Hospital Opava OpavaCzech Republic

5. Department of Haematology – Oncology University Hospital OlomoucCzech Republic

6. Hospital Agel Nový JičínCzech Republic

7. Department of Haematology University Hospital OstravaCzech Republic

8. Department of Haematology University Hospital Královské Vinohrady Prague Czech Republic

Funder

Roche

Bayer Schering

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17373

Reference36 articles.

1. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology

2. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies

3. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

4. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

5. Conventional Dose Fludarabine-based Regimens are Effective but have Excessive Toxicity in Elderly Patients with Refractory Chronic Lymphocytic Leukemia

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL;Blood Advances;2024-02-14

2. Modern approach to the treatment of chronic lymphocytic leukemia;Onkologie;2023-10-05

3. Nucleoside-based anticancer drugs: Mechanism of action and drug resistance;Biochemical Pharmacology;2023-09

4. FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL;Clinical Hematology International;2022-09-14

5. The CLL comorbidity index in a population-based cohort: a tool for clinical care and research;Blood Advances;2022-04-25